Hansa Biopharma enters into collaboration with Genethon

The collaboration will assess Hansa Biopharma’s imlifidase as pre-treatment to Genethon’s gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Credit: National Cancer Institute on Unsplash.